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cu and Zn isotope ratio variations 
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We have examined potential changes in the isotopic compositions of Fe, Cu and Zn (using multi‑
collector inductively coupled plasma‑mass spectrometry) and the corresponding concentrations (using 
inductively coupled plasma‑atomic emission spectrometry) in plasma from hematological malignancy 
(HM) patients and assessed their prognostic capability. Together with clinical laboratory test values, 
data were examined in view of a 5‑years survival prediction. Plasma Cu and Zn isotope ratios and their 
concentrations were significantly different in HM patients compared to matched controls (P < 0.05). 
Both δ65Cu and δ66Zn values showed significant mortality hazard ratios (HRs) in HM. The group of 
patients with decreased δ65Cu and increased δ66Zn values showed significantly poorer survival from 
the early phase (HR 3.9; P = 0.001), forming a unique cohort not identified based on laboratory test 
values. Well‑known prognostic factors for HM, such as the creatinine level, and anemia‑related values 
were highly correlated with the δ66Zn value (P < 0.05). Time‑dependent ROC curves based on the δ65cu 
or δ66Zn value were similar to that based on the creatinine concentration (a well‑known prognostic 
factor in HM), indicating that δ65Cu or δ66Zn values are useful for prognosis of HM. Variations in stable 
isotope ratios of essential mineral elements have thus been shown to reflect alterations in their 
homeostasis due to physiological changes in malignancies with higher sensitivity than concentrations 
do.
Essential metals play a pivotal role in numerous biological processes, especially for maintaining protein structure 
and in cellular biochemical reactions. For redox-active elements, such as Cu and Fe, the electron transfer between 
the reduced and the oxidized states is exploited for catalysis of protein activities, such as energy production and 
oxidative  processes1. As a result of its redox activity, such a metal can also damage proteins, lipids, nucleic acids, 
and other cellular compounds when present in excess. Zinc, a redox-inert element, is present in one-tenth of the 
proteins in the human body and participates in many cellular signalling  cascades2.
Alteration of the concentrations of Cu and Zn in serum has been widely described in cancer, particularly 
in the case of hematologic malignancies (HMs). HMs can be roughly classified into leukemia, lymphoma, and 
myeloma; while all these diseases affect the hematopoietic system, they show diverse features. HM, as well as 
other cancer types, has been associated to increased oxidative stress, which can be related to Cu  toxicity3 and/
or reduced activity of Cu/Zn superoxide dismutase (SOD)4. Cu/Zn SOD is a free radical scavenger, the role of 
which is maintaining a low level of reactive oxygen species. A meta-analysis on acute leukemia demonstrated 
that the serum Cu concentration is significantly higher, while that of Zn is significantly lower in patients than 
in  controls5. This pattern for Cu and Zn serum concentrations was also observed in a meta-analysis of bladder 
 cancer6 and was also associated with an increased risk of oral  cancer7. Other studies also found serum Cu and/
or Zn concentrations deviating from the control range, but without following this specific  pattern5, 6, 8. Despite 
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the large amount of epidemiological data linking metals to HM, their clinical impact on the disease remains 
unclear. Metal concentrations in serum are tightly controlled, but they vary widely among individuals as they 
are influenced by many parameters unrelated to either element status or cancer, e.g., the presence of infection, 
inflammation, age, gender, diet, smoking,  etc9.
High-precision isotopic analysis has been shown to be a suitable tool for detecting alterations in metal homeo-
stasis due to physiological  changes10, 11, also those related to cancer. The serum and whole blood Cu isotopic 
compositions have been shown to be significantly lighter (enriched in the light 63Cu isotope) in breast cancer, 
colorectal  cancer12, and hepatocellular carcinoma  patients13 compared to controls. Reversely, the Cu isotopic 
composition in tumour tissue is heavier (enriched in the 65Cu isotope) than that in adjacent healthy  tissue13, 14. 
No differences were established in the serum and whole blood Zn isotopic composition in breast  cancer15, colon 
cancer, and prostate cancer  patients11 compared to that of controls, but the breast tumour tissue was shown to 
be enriched in the light 64Zn isotope compared to healthy  tissue15. Metal isotopic compositions may thus reflect 
changes in metal homeostasis with higher sensitivity than metal concentrations do, such that high-precision 
isotopic analysis can detect physiological abnormalities at an early  stage12, 16.
In this study, we examined potential changes in the isotopic compositions of Fe, Cu and Zn (using multi-col-
lector inductively coupled plasma-mass spectrometry MC-ICP-MS) and the corresponding metal concentrations 
(using inductively coupled plasma-atomic emission spectrometry ICP-AES) in plasma of HM patients compared 
to age- and gender-matched healthy controls. The prognostic capability of the metal isotope ratios was examined 
via survival analyses, including mortality hazard ratios (HRs), survival curves and time-dependent ROC analysis.
Results
Comparison between HM patients and controls. Patients suffering from HMs, including acute 
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin’s 
lymphoma (NHL), were recruited from the hospital of the National Center for Global Health and Medicine 
(NCGM) in Tokyo, Japan. Patients were followed up for a period of 5 years from the first visit onwards or to 
death for survival analysis. As controls, gender- and age-matched healthy cases were used. Figure 1 presents the 
flowchart of this prospective study.
Establishing the isotopic variability within a healthy population is crucial, as the reference range might be 
affected by nutritional and metal status, basal metabolic rate, geographical origin, gender, age, etc. Although the 
Fe, Cu and Zn isotopic compositions in blood plasma, serum, red blood cells or whole blood of healthy indi-
viduals from different geographical origins have been documented, data are still scarce and furthermore, only 
a few works reported the isotopic composition of the three elements for the same sample/individual17, 18. The 
plasma Fe, Cu and Zn isotopic compositions for each individual are provided in Table S1. Overall, the plasma 
δ56Fe values for healthy middle-aged Japanese individuals (controls) were within the range of the serum δ56Fe 
values of Thai healthy individuals, which are characterized by a lighter plasma/serum Fe isotopic composition 
than reference populations from other geographical areas (Figs. S1A,B), hypothetically attributed to different 
dietary habits and Fe nutritional  status19–21. The δ65Cu values in plasma of Japanese healthy individuals were in 
agreement with those reported in serum for healthy individuals from other geographical  areas16–18, 22, 23 (Fig. S1C), 
while the δ66Zn values in plasma were slightly heavier than those in serum from healthy populations of other 
Figure 1.  Diagram describing the selection of patient/control samples included in the study.
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geographical origins (Fig. S1D), potentially associated to the sample type and/or dietary  habits24. In this study, 
we used a Japanese cohort (all individuals also residing in Japan) for further analysis.
The Fe, Cu and Zn isotopic compositions, their concentrations, as well as the laboratory test values, for both 
the HM patients and controls are compiled in Table 1. HM patients showed plasma δ65Cu and δ66Zn values 
that are significantly different from those in the control group (P < 0.001 and P = 0.007, respectively), whereas 
the δ56Fe value was not significantly different (P = 0.09). Box plots for Fe, Cu and Zn isotopic compositions are 
shown in Fig. 2A–C. The plasma δ65Cu value tended to decrease, whereas the δ66Zn value tended to increase in 
HM patients compared to controls. 
While the concentrations of Fe and Cu were significantly elevated (by ca. 30 and 45%, respectively), the Zn 
concentration was ca. 20% lower in HM patients than in controls. Also, laboratory test values, which are currently 
Table 1.  Characteristics and (bio)chemical data for the HM patients and controls. Kolmogorov–Smirnov test. 
**P < 0.01; ‡SD: standard deviation; ‡‡ICR: inter-quartile range. † Number of healthy controls was 47 for δ65Cu 
and δ66Zn, and 44 for δ56Fe. † Number of HM patients was 39 for δ65Cu and δ66Zn, and 38 for δ56Fe. †† ALL 
Acute Lymphoblastic Leukemia, AML Acute Myeloid Leukemia, MM Multiple Myeloma, NHL Non-Hodgkin’s 
lymphoma, Abb. abbreviation.
Control Hematological malignancy (HM)
Sample number 50† 40†
Age: mean  (SD‡) 59.3 (12.2) 57.3 (15.2)
Female/Male 25/25 19/21
Disease (%)
ALL†† 0 (0%) 5 (12.5%)
AML†† 0 (0%) 17 (42.5%)
NM†† 0 (0%) 9 (22.5%)
NHL†† 0 (0%) 9 (22.5%)
Isotope ratios
Mean  (SD‡) Median  (ICR‡‡) Mean  (SD‡) Median  (ICR‡‡) P valueItems Unit
δ56Fe ‰ − 2.77 (0.40) − 2.84 (− 3.0, − 2.7) − 2.90 (0.46) − 3.00 (− 3.1, − 2.7) 0.096
δ65Cu ‰ − 0.21 (0.17) − 0.21 (− 0.26, − 0.14) − 0.43 (0.29) − 0.42 (− 0.61, − 0.30)  < 0.001**
δ66Zn ‰ 0.25 (0.08) 0.25 (0.22, 0.27) 0.34 (0.12) 0.33 (0.26, 0.39) 0.007**
Element concentrations
Mean  (SD‡) Median  (ICR‡‡) Mean  (SD‡) Median  (ICR‡‡) P valueItems Unit
Fe  × 10–1 µg/mL 11 (3.2) 9.6 (8.7, 11) 14 (6.1) 14 (10, 17) 0.007**
Cu  × 10–1 µg/mL 7.6 (1.1) 7.5 (7.1, 7.8) 11 (4.0) 9.9 (8.8, 11)  < 0.001**
Zn  × 10–1 µg/mL 7.1 (0.86) 7.0 (6.7, 7.5) 5.7 (1.3) 5.7 (5.3, 6.2)  < 0.001**
Laboratory tests
Mean  (SD‡) Median  (ICR‡‡) Mean  (SD‡) Median  (ICR‡‡) P valueItems Abb.†† unit
White blood cells WBC  × 103/mL 5.1 (1.3) 5.3 (4.7, 5.5) 47 (134) 6.3 (3.0, 0.10) 0.001**
Blasts BLAS  × 103/mL 0.0 (0.0) 0.0 (0.0, 0.0) 17 (43) 0.0 (0.0, 3.6)  < 0.001**
Neutrophils NEU  × 103/mL 3.0 (1.0) 2.7 (2.5, 3.4) 5.7 (9.2) 2.6 (1.0, 4.4)  < 0.001**
Monocytes MON  × 102/mL 0.22 (0.13) 0.21 (0.16, 0.26) 11 (66) 0.13 (0.07, 0.32) 0.17
Eosinophils EOS  × 102/mL 1.5 (1.2) 1.3 (0.76, 1.7) 0.80 (1.9) 0.0 (0.0, 0.20)  < 0.001**
Basophils BAS  × 101/mL 4.3 (4.9) 3.8 (0.0, 5.7) 1.1 (3.4) 0.0 (0.0, 0.0) 0.011
Lymphocites LYM  × 103/mL 1.7 (0.59) 1.7 (1.3, 1.9) 12 (46) 1.2 (0.81, 2.3) 0.008**
Red blood cells RBC  × 105/mL 4.7 (0.43) 4.8 (4.6, 4.9) 2.9 (0.86) 2.9 (2.4, 3.5)  < 0.001**
Hematocrit Ht % 44 (3.7) 44 (42, 45) 28 (7.6) 27 (23, 32)  < 0.001**
Hemoglobin Hb  × 101 g/dL 1.4 (0.14) 1.4 (1.4, 1.5) 0.93 (0.26) 0.89 (0.78, 1.1)  < 0.001**
Platelets PLT  × 105/mL 2.3 (0.53) 2.3 (2.0, 2.5) 1.2 (1.1) 0.85 (0.46, 1.6)  < 0.001**
Albumin ALB  × 100 g/dL 4.4 (0.23) 4.4 (4.3, 4.4) 3.5 (0.69) 3.7 (3.3, 3.9)  < 0.001**
Total bilirubin TBI  × 100 mg/dL 1.1 (0.36) 1.0 (1.0, 1.1) 0.82 (0.60) 0.70 (0.50, 0.80)  < 0.001**
Aspartate aminotransferase GOT  × 101 U/L 2.3 (1.1) 2.2 (1.9, 2.4) 3.2 (2.9) 2.2 (1.9, 2.7) 0.40
Alanine aminotransferase GPT  × 101 U/L 2.5 (1.7) 1.9 (1.8, 2.5) 3.0 (4.7) 1.8 (1.4, 2.3) 0.59
Lactate dehydrogenase LDH  × 102 U/L 1.9 (0.56) 1.8 (1.7, 1.9) 4.3 (4.0) 2.6 (2.4, 4.0)  < 0.001**
Blood urea nitrogen BUN  × 101 mg/dL 1.6 (0.43) 1.5 (1.4, 1.7) 1.7 (1.1) 1.4 (1.2, 1.6) 0.24
Creatinine CRE  × 10–1 mg/dL 7.3 (1.7) 7.2 (6.7, 7.8) 9.1 (5.7) 7.1 (6.2, 9.0) 0.16
Uric acid UA  × 100 mg/dL 5.6 (1.3) 5.4 (4.8, 6.3) 6.4 (3.0) 5.7 (4.5, 7.0) 0.33
Sodium Na  × 102 mEq/L 1.4 (0.02) 1.4 (1.4, 1.4) 1.4 (0.06) 1.4 (1.4, 1.4)  < 0.001**
Potasium K  × 100 mEq/L 4.1 (0.32) 4.1 (4.0, 4.2) 3.9 (0.50) 3.9 (3.7, 4.2) 0.044
Chloride Cl  × 102 mEq/L 1.0 (0.15) 1.1 (1.1, 1.1) 1.0 (0.042) 1.0 (1.0, 1.0) 0.002**
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used for diagnosing HMs, deviated from the reference values in a highly significant way (P < 0.01, Table 1). The 
alteration of plasma metal concentrations (elevated for Cu and reduced for Zn) and laboratory test values in HM 
patients are consistent with reported  data5–8, 25.
Five‑year prognosis in HM patients using the metal isotope ratios. Mortality hazard ratios (HRs) 
for 5-years survival were determined for Fe, Cu, and Zn isotope ratios and the corresponding concentrations 
(Fig. 3A,B, respectively). δ66Zn showed a HR higher than 1 (HR: 68, P = 0.03, Fig. 3A), suggesting a significantly 
higher risk of mortality in the case of increased δ66Zn values. δ65Cu showed a HR lower than 1 (HR: 0.14, 
Figure 2.  Box plots (created using SigmaPlot version 13, Systat Software, Inc, San Jose, CA, USA) for the 
isotopic compositions of Fe (A), Cu (B) and Zn (C) in plasma of HM patients and controls. These box plots 
compile the median, quartiles and extreme values; individual dots are outliers.
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P = 0.02, Fig. 3A), suggesting a significantly higher risk of mortality in the case of decreased δ65Cu values. On 
the other hand, δ56Fe (Fig. 3A), and Fe, Cu, Zn concentrations (Fig. 3B) did not show any significant influence 
on the HR.
We next examined survival curves using the combination of δ65Cu and δ66Zn data, both of which showed a 
significant influence on the HR. Hierarchical clustering analysis (HCA) was applied for grouping of the patients. 
HCA using the δ65Cu and δ66Zn values classified the HM patients into two groups at the highest hierarchy (G1 
and the other group, see Fig. 4A). G1 was formed by patients showing high δ66Zn and low δ65Cu values compared 
to controls and it showed significantly poorer survival (HR at 60 months: 3.87, P = 0.001, Fig. 4B). Most patients 
in G1 died within 15 months (HR at 15 months: 5.12, 95% CI:1.81–14.47). These data suggest that G1 showed a 
high risk of mortality in an early phase. A similar approach was performed using the Cu and Zn concentrations 
(Fig. 4C,D); however, there was no significant difference between the G2 group and the other group found upon 
HCA (Fig. 4D).
The G1 group identified on the basis of isotope ratios was not significantly different from the other group in 
terms of disease type, age, and gender (Fig. S2). These data suggest that poor survival within G1 was not depend-
ent on any difference related to disease type, age or gender and thus, they indicate the potential capability of the 
Cu and Zn isotopic compositions as prognostic factors in HM.
Correlations of the metal isotope ratios with laboratory test values. To understand the mecha-
nisms affecting the isotope ratios, thus rendering them potentially useful for prognosis in HM, we next car-
ried out Principal Component Analysis (PCA) using the isotope ratios and laboratory test values. The PCA 
biplot showed arrows of varied directions and lengths (Fig. 5A). Notably, δ66Zn formed a subgroup with three 
major laboratory test values related to renal function (uric acid concentration UA, creatinine concentration CRE 
and blood urea nitrogen concentration BUN) in HM patients, and the direction of the arrows was extended in 
the same direction (Fig. 5A, right). These data suggest a positive correlation between δ66Zn and renal param-
eters. On the other hand, the δ66Zn in controls did not lead to the formation of any obvious subgroup (Fig. 5A, 
left). Spearman’s rho test confirmed that δ66Zn correlated with UA, CRE and BUN (Fig. 5B, P < 0.05). These 
correlations became remarkably significant in the HM patients, whereas BUN was significantly correlated with 
δ66Zn in both HMs and controls. δ66Zn also correlated significantly with two laboratory test values related to 
anemia, i.e. the hematocrit level Ht and the hemoglobin level Hb, in HM patients (Spearman’s rho test, P = 0.007 
and P = 0.006, respectively, Fig. S3.A). δ56Fe correlated with the platelets number PLT, which provides informa-
Figure 3.  Mortality hazard ratios for a 5-years interval. Mortality hazard ratios (HR) were obtained by cox-
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tion on the bleeding tendency, and is often enhanced in leukemia (P = 0.03, Fig. S3A). In contrast, Fe, Cu and 
Zn concentrations did not show any significant correlation with renal function nor anemia in HM, while in 
the controls, these concentrations showed a correlation with the anemia-related values (RBC, Ht, Hb) and PLT 
(Fig. S3B).
We next examined to what extent those laboratory parameters that correlated with the isotope ratios could 
contribute to prognosis in HM and were related to G1. HCA using UA, CRE, BUN values classified HM patients 
into two groups (G3 and the other group, see Fig. 5C). All patients in G3 died within 15 months, and G3 showed 
a significantly poorer survival (HR 6.18, P = 0.001, Fig. 5D). In fact, G3 patients showed extremely poor results for 
CRE (Arrowheads, Fig. S4). These data were consistent with previous findings that identified CRE as a prognostic 
marker in HM  patients26–29. Notably, only two patients in G3 also belonged to G1 (Fig. 5E). A similar approach 
was performed using Ht, Hb, PLT (Fig. S5A), and 6 or 20 of the laboratory test values (see Figs. S5B and S5C). 
There was no significant difference in survival between each of these clustering groups (G4, G5, G6) and the 
corresponding other group (Fig. S5A–C, right). These data suggest that only renal parameters including a well-
known prognostic marker could reveal a risk group of early mortality (G3) that partially overlapped with G1.
Time‑dependent ROC curves for δ65Cu and δ66Zn. To understand the capability of the δ65Cu or 
δ66Zn values as potential new prognostic factors of HMs, we next examined the corresponding time-dependent 
receiver operating characteristic (ROC) curves. The δ65Cu or δ66Zn value shows a similar area under the curve 
(AUC) as does CRE, a well-known prognostic factor in  HM26–29 (Fig. 6).
Discussion
Biomarkers allowing diagnosis in an early stage of a disease, and prognostic markers for predicting a patient’s 
survival are of outmost importance. To date, differences in the isotopic compositions of essential metals (Cu 
and Ca) in serum/red blood cells have been shown between cancer patients and  controls12, 13, 30 and although the 
Figure 4.  Survival analysis based on the combination of δ65Cu and δ66Zn values. (A) Hierarchical clustering 
analysis classified HM patients into two groups (G1 and the other group) using the δ65Cu and δ66Zn values. (B) 
Survival curves for G1 and the other group obtained by Kaplan-Meier analysis. G1 showed significantly poor 
survival from the early phase (P = 0.001). (C) Similar classification as in (A), but using the corresponding Cu and 
Zn concentrations. (D) HM patients were classified into two groups (G2 and the other group). Survival curves 
for G2 and the other group obtained by Kaplan–Meier analysis. The two groups did not show a significant 
difference. Patients are numbered according to the δ66Zn value (descending order); red coloured numbers 
correspond to patients in G1; HR, hazard ratio with 95% confidence interval.
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Figure 5.  Correlations between the isotopic compositions and laboratory test values. (A) Principal component analysis (PCA) 
using the isotopic compositions and laboratory test values. PCA was performed using JMP (version 13.2.0, SAS Institute inc., 
Cary NC, USA). The red circle indicates a characteristic distribution of items in controls or HM patients (Adobe Photoshop 
CC, version 18.1.6, Adobe System Inc., CA, USA). (B) Correlations between the Zn isotopic composition and renal function 
parameters. The values above the bars correspond to the P-values for each correlation. Black bars: values for HM patients; grey 
bars: values for healthy controls, *P < 0.05. (C) Hierarchical clustering analysis using UA, CRE, BUN (renal function) classified 
HM patients into two groups (G3 and the other group). (D) Survival curves for G3 and the other group were obtained by 
Kaplan-Meier analysis. All patients in G3 died within 15 months, and G3 showed a significantly poor survival (P = 0.001). (E) 
Venn diagrams illustrating the partial overlap between G3 and G1. Two patients in G3 were also included in G1. Patients are 
numbered according to the δ66Zn value (descending order); red coloured numbers correspond to patients in G1. HR, hazard 
ratio with 95% confidence interval.
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mechanisms or processes inducing these isotopic effects still have to be elucidated in detail, some interpretations 
have already been given. It has been suggested that the low serum δ65Cu values may be associated to changes 
in metalloproteins and/or reallocation of the Cu bound to these  proteins13. Heavier isotopes are preferentially 
bound to amino acids with harder ligands, involving metal binding to nitrogen and oxygen (e.g., histidine and 
phosphate, respectively), while the lighter isotopes prefer binding to softer ligands, involving sulphur (such as 
cysteine and glutathione). Bonds involving the reduced metal form tend to be enriched in the light  isotope31. 
These findings suggested that alterations in the natural isotopic compositions are associated with the development 
of diseases involved in the disruption of metal homeostasis. In this study, we have demonstrated the association 
between the isotopic compositions of Cu and Zn and prognosis for HM patients.
The plasma Zn isotopic composition of the HM patients was heavier than that of controls. In HM patients, 
δ66Zn values were correlated with renal dysfunction via three major test values, and with anemia and bleed-
ing-related values, which are typically affected in  HMs32. Notably, CRE is a well-known prognostic factor of 
 HM26–29. In fact, CRE showed a significant mortality HR by COX regression analysis (HR 2.49: 95% CI, 1.30–4.76, 
P = 0.006). Additionally, anemia and the bleeding tendency are aggravating factors for HM prognosis. These 
correlations may at least partially explain why δ66Zn indicates the risk of mortality.
On the other hand, we could not find out any relation between δ65Cu values and laboratory test values. The 
Warburg effect has been proposed as an explanation for the light plasma/serum Cu isotopic composition in 
malignancy patients: a preferential chelation of the heavy 65Cu isotope in tumour cells, with the subsequent 
preferential release of the light 63Cu isotope into plasma or  serum12, which was reported for various types of 
 malignancies12, 13, and is consistent with our work on HM. Notably, although HM is a ‘non-solid tumour type’, it 
also causes the plasma Cu isotopic composition to be light, as was established for serum in solid tumours. As a 
result, the origin of this observation might be more complex than preferential 65Cu uptake in the solid tumour 
and preferential excretion of 63Cu into the blood stream. The enrichment in the light 63Cu isotope in plasma could 
be related to tumour cell proliferation. However, we could not see any correlation between the δ65Cu value and 
increased white cell numbers (WBC, Blasts, etc.) due to tumorigenesis in HM, nor between the δ65Cu value and 
UA or lactate dehydrogenase LDH levels, which are often influenced by tumour cell proliferation in HM. While 
leukemia results in abnormal cells in peripheral blood, lymphoma (NHL) and myeloma (MM) are mainly located 
at lymph nodes and in bone marrow, respectively. Therefore, next to specific cells in peripheral blood, also cells 
in bone marrow or lymph nodes that chelate the heavy 65Cu isotope, may play an important role. Further studies 
are necessary to reveal the mechanism of decreased δ65Cu values in these malignancies.
Notably, our study demonstrated that the combination of decreased δ65Cu and increased δ66Zn values, cor-
responding to the G1 group in this study, showed significantly poorer survival from the early phase. G1 partially 
overlapped with G3 with high risk of mortality due to deteriorated renal function. However, the rest of the HM 
patients in the G1 group formed a unique cohort revealed by Cu and Zn isotope ratios only. In fact, most of the 
patients in G1 had a similar range of renal function parameters as the rest of the HM patients, except for the two 
cases in G3 (Figs. 5C,E and S4). On the other hand, G1 showed remarkably worse laboratory test values related 
to anemia and bleeding tendency compared to the rest of the HM patients (Fig. S4). However, critical survival 
Figure 6.  Time-dependent receiver operating characteristic (ROC) curve for δ65Cu, δ66Zn and CRE 
(creatinine), a well-known prognostic factor in HM; AUC, area under the curve.
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of G1 could not be explained by anemia, increased bleeding tendency and a minor impact on renal dysfunction 
only. There have to be further so far unrevealed mechanisms explaining the decreased δ65Cu and increased δ66Zn 
values. Further clinical studies are required to understand the mechanisms for decreased δ65Cu and increased 
δ66Zn values that predict poor survival in HM. It was noticeable that the δ65Cu or δ66Zn values showed a similar 
time-dependent ROC curve to CRE. Overall, our data suggest that δ65Cu or δ66Zn contained equally significant, 
but different prognostic information, which matched that offered by the well-known prognostic factor CRE. The 
δ65Cu and δ66Zn values could be interesting new candidates as prognostic factors in HM patients.
conclusions
High-precision isotopic analysis using multi-collector ICP-mass spectrometry revealed significant changes in 
the isotopic compositions of Cu (isotopically lighter) and Zn (isotopically heavier) in the plasma of HM patients. 
Patients with decreased δ65Cu and increased δ66Zn showed significantly poorer survival from the early phase, 
forming a unique cohort not revealed based on laboratory test values. The assessment of the HRs and the time-
dependent ROC curves suggest that the δ65Cu and δ66Zn values are useful for the prediction of survival in HM 
patients. This study was exploratory in nature and future studies with a larger number of patients in a multi-
center study are recommended.
Materials and methods
patients. Patients suffering from HMs, defined according to the 2008 WHO  classification33, were recruited 
on their first visit to the hospital of the National Center for Global Health and Medicine (NCGM) in Tokyo, 
Japan, from April 2008 to July 2009. Patients with chemotherapy at sampling were excluded. In total, 47 patients 
suffering from HMs were selected (Table 1). Patients were followed up from the first visit to April 2014 or to 
death for survival analysis. The median follow-up time was 33.3  months. A set of 22 basic laboratory tests, 
including complete blood counts (CBC), were carried out at the NCGM hospital. As controls, gender- and age-
matched healthy cases, visiting for a regular medical check-up (as required by the national health insurance in 
Japan) between May 2009 and June 2009, were recruited. All samples were obtained following fasting.
Laboratory tests. A total of 22 basic and CBC laboratory tests were completed in the routine medicine 
division of the NCGM hospital, including: counting the number of white blood cells (WBC), blast cells (BLAS), 
neutrophils (NEU), monocytes (MON), eosinophils (EOS), basophils (BAS), lymphocytes (LYM) and red blood 
cells (RBC) and the determination of the levels of hematocrit (Ht), hemoglobin (Hb), platelets (PLT), albumin 
(ALB), total bilirubin (TBI), aspartate aminotransferase (GOT), alanine aminotransferase (GPT), lactate dehy-
drogenase (LDH), urea nitrogen (BUN), creatinine (CRE), uric acid (UA), sodium (Na), potassium (K), and 
chloride (Cl).
Sample preparation. Winged needle (MN-SVS23BS, Terumo, Tokyo, Japan) vacuum blood collection 
tubes (Venoject II VP-CW052K, Terumo, Tokyo, Japan) were used to collect 4 mL of peripheral blood. Labora-
tory tests followed the sampling immediately. The collection tubes were centrifuged at 250 × g for 20 min at 4 °C, 
after which the supernatant plasma fraction was collected in a centrifuge tube (15 mL, #2327-015, Iwaki, Tokyo, 
Japan). An aliquot of plasma was used for elemental analysis (at NCGM) and another aliquot was used for iso-
topic analysis (at Ghent University). Samples for isotopic analysis were stored in pre-cleaned Eppendorf tubes at 
− 20 °C and transported on dry ice.
Sample preparation for isotopic analysis was performed in a class-10 clean room (PicoTrace, Göttingen, Ger-
many). Ultra-pure water acquired from a Milli-Q water purification system (Merck Millipore, Molsheim, France) 
was used throughout. Pro-analysis grade  HNO3 (Chem-Lab, Zedelgem, Belgium) and HCl (Fisher Chemicals, 
Loughborough, UK) were further purified by subboiling distillation in a Savillex DST-4000 acid purification 
system (Savillex Corporation, Eden Prairie, MN, USA) prior to usage. The serum samples were digested with a 
mixture (4:1 v/v) of 14 M  HNO3 and 9.8 M  H2O2 (Sigma Aldrich, Belgium) kept at 110 °C for 18 h. The digests 
were evaporated to dryness and re-dissolved in 5 mL of a solution containing 8 M HCl and a small amount of 
 H2O2 (~ 0.001%) for the sequential isolation of Cu, Fe and Zn via anion exchange chromatography using 1 mL 
of AG-MP1 resin. The Cu fraction was eluted using 9 mL of 5 M HCl +  ~ 0.001%  H2O2, the Fe fraction using 
7 mL of 0.6 M HCl and the Zn fraction using 7 mL of 0.7 M  HNO3. The Cu fractions were subjected to a second 
column pass to ensure a Na/Cu ratio < 2 in all  solutions17, 22. The pure fractions thus obtained were subjected to 
two steps of drying and re-dissolution in 14 M  HNO3 to remove residual chlorides and, were finally re-dissolved 
in 0.5 mL of 0.42 M  HNO3 for high-precision isotope ratio measurements using MC-ICP-MS. For elemental 
analysis, plasma samples were digested with 0.5 mL of 14 M  HNO3 (Tamapure-AA-100, Tama Chemical Co. Ltd., 
Kanagawa, Japan) at 180 °C for 20 min using an ETHOS 1 microwave dissolution unit (Milestone, Shelton, CT, 
USA) and then diluted with Milli-Q water (Nihon Millipore, Tokyo, Japan) to a final volume of 5 mL.
Determination of metal isotope ratios and concentrations. e, Cu and Zn isotope ratios were meas-
ured using a Neptune multi-collector inductively coupled plasma-mass spectrometry (MC-ICP-MS) instrument 
(ThermoScientific, Bremen, Germany). The bias caused by instrumental discrimination was corrected for by 
means of a combination of internal correction (internal standard) and external correction (external standard). 
Ni, Ga and Cu (Inorganic Ventures, VA, USA) were used as internal standard for Fe, Cu and Zn isotope ratio 
measurements, respectively. Internal correction was done according to the revised Russell’s  law34. For external 
correction, the samples and the external standard were measured in a sample-standard bracketing approach 
(SSB). The concentrations of standards and samples were always matched within ± 5%. The reference materials 
Cu NIST SRM-976 (NIST, Gaithersburg, MD, USA), Fe IRMM-014 and Zn IRMM-3702 (IRMM, Geel, Bel-
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:16389  | https://doi.org/10.1038/s41598-020-71764-7
www.nature.com/scientificreports/
gium) were used as external isotopic standards. The isotope ratios were expressed in δ-values (in ‰), calculated 
as indicated in Eq. (1).
where a and b correspond to the mass numbers of the isotopes of interest, X is the target element and R an isotope 
ratio of the target element.
Fe, Cu and Zn standard solutions (Inorganic Ventures) that were previously characterized isotopically were 
measured every five samples for quality assurance/quality control (QA/QC) of the measurements. The δ-values 
(mean ± 2SE) obtained along this work were 0.23 ± 0.01‰ for δ65Cu (N = 53), 0.46 ± 0.02‰ for δ56Fe (N = 53), 
and − 7.04 ± 0.01‰ for δ66Zn (N = 40), which all agreed well with the data from previous  studies17, 21, 22.
The expanded uncertainty, which characterizes the dispersion of the δ-values in the plasma samples, was 
0.05‰ for the δ65Cu, 0.18‰ for the δ56Fe, and 0.06‰ for the δ66Zn.
Total concentrations of Fe, Cu and Zn were determined using ICP-AES (Optima 4300DV, PerkinElmer, 
Waltham, MA, USA). The signal at the optimal wavelength for each element (Fe: 259.939 nm; Cu: 327.393 
nm; Zn: 213.857 nm) was used for quantification. Data were validated using a human serum reference material 
(Seronorm, Sero, Billingstad, Norway, Table S2).
Statistical analysis. Data standardization, correlation analysis, cox regression and survival analysis were 
performed with SPSS (version 26; IBM, Armonk, NY, USA). The limit of significance for all analyses was set 
at P = 0.05. Group comparisons were carried out using the Kolmogorov–Smirnov test for continuous variables 
and the chi-square test for categorical variables using GraphPad Prism software (version 8; GraphPad Software 
Inc., San Diego, CA, USA). Principal component analysis (PCA) was performed using JMP (version 13.2.0; SAS 
Institute inc., Cary NC, USA). A score scatter plot was generated to obtain an overview of sample clustering 
and to detect potential outliers. Varimax rotation was applied for data interpretation. Correlation coefficients 
between parameters were assessed using the Spearman rank test. To examine correlation between survival and 
the elemental concentrations/isotope ratios, the hazard ratios (HR) with 95% confidence intervals (CI) were 
calculated by univariate and multivariate Cox regression analyses. The element concentration/isotope ratio was 
considered significant when the log-rank test P-value was < 0.05 in the univariate Cox regression analysis and 
was then selected for multivariate analysis. Hierarchical clustering analysis (HCA) was performed using Ward’s 
methods by JMP (version 13.2.0; SAS Institute inc. Cary, NC, USA), and validated using the R hclust func-
tion (version 3.6.3). The overall survival of each group was calculated using the Kaplan–Meier method. Two 
survival curves were compared by the Gehan–Breslow–Wilcoxon test. The Cox proportional hazard models 
were used to estimate HRs and 95% CIs for comparison of death event rates between G1 and the other groups. 
Multivariate Cox regression analysis was performed using the survival package (version 3.1.8) in the R language 
(version 3.5.0)35. Subsequently, the time-dependent receiver operating characteristic (ROC) curve analysis was 
conducted using R with the survival ROC package (version 1.0.3)36. The results were expressed as indicated in 
the STROBE guidelines.
ethical approval. This study was performed following the national regulations and institutional poli-
cies and was approved by the committees of the National Center for Global Health and Medicine (#NCGM-
G-003014–00) in accordance with the Helsinki Declaration of the World Medical Association. All subjects pro-
vided informed consent.
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